NCT06322238View on ClinicalTrials.gov

Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions
Pharmacogenomic Drug InteractionSide Effect of DrugIneffective Drug ActionDrug Metabolism, Poor, CYP2D6-RelatedDrug Metabolism, Poor, CYP2C19-Related
Interventions
DIAGNOSTIC_TEST

PGx panel test

In this prospective, non-randomized, step-wedge design controlled clinical study (PREPARE-MAYO Rochester, Mayo Clinic Health System), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which CPIC guidelines are available.

Trial Locations (1)

55902

RECRUITING

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT06322238 - Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice: | Biotech Hunter | Biotech Hunter